Abstract | BACKGROUND: OBJECTIVE: Our objective was to evaluate rhPTH (1-34) safety and efficacy in pediatric patients with genetically proved syndromic hypoparathyroidism. METHODS: RESULTS: rhPTH treatment allowed complete calcium and vitamin D withdrawal in two patients, calcium withdrawal in three and reduction of vitamin D dose in two. During rhPTH (1-34), mean blood calcium, phosphorus, and alkaline phosphatase were not significantly modified, whereas significant reduction of the calciuria-to-creatininuria ratio (0.55±0.31 vs. 0.1±0.1, p=0.02) was obtained. The number of tetanic episodes was reduced in four patients during teriparatide treatment compared to conventional treatment. CONCLUSION: In children with syndromic hypoparathyroidism, substitutive treatment with rhPTH (1-34) maintains adequate blood calcium levels and allows prompt normalization of urinary calcium excretion, through direct action on the kidney and through calcium and vitamin D therapy layoff.
|
Authors | Patrizia Matarazzo, Gerdi Tuli, Ludovica Fiore, Alessandro Mussa, Francesca Feyles, Valentina Peiretti, Roberto Lala |
Journal | Journal of pediatric endocrinology & metabolism : JPEM
(J Pediatr Endocrinol Metab)
Vol. 27
Issue 1-2
Pg. 53-9
(Jan 2014)
ISSN: 2191-0251 [Electronic] Germany |
PMID | 23945122
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Child
- Female
- Humans
- Hypoparathyroidism
(drug therapy)
- Male
- Teriparatide
(therapeutic use)
|